Par Pharmaceuticals, Inc.

Par Pharmaceutical, Inc. (commonly "Par") is a U.S. generic-drug developer, manufacturer and marketer. It was incorporated in 1978 as the operating subsidiary of Par Pharmaceutical Companies, Inc., a Delaware holding company, and was long based at 300 Tice Boulevard, Woodcliff Lake, N.J., later at Ram Ridge Road, Chestnut Ridge, N.Y. TPG took the business private in 2012 for about $1.9 billion; Endo International plc bought it in 2015 for roughly $8.05 billion. After Endo's Chapter 11 restructuring and the July 31, 2025 Mallinckrodt–Endo merger, the combined generics and sterile-injectables business was spun off as Par Health (announced November 2025), headquartered in St. Louis, with a workforce described as "in the thousands." Par is privately held; no public ticker.

Operations. Par develops, manufactures and distributes generic prescription drugs — oral solids (tablets, capsules), extended-release and immediate-release products, liquids, controlled substances, sterile injectables and active pharmaceutical ingredients — plus a smaller branded/sterile-injectables line (e.g., Vasostrict, Nascobal) and authorized generics. Its product portfolios have been described at roughly 200 products; Endo's Par segment reported about $1.24 billion in 2014, and Par Health reported $337.1 million in Q3 2025 sales. It operates U.S. plants (New York, New Jersey, Michigan, California historically) and sites in India.

Litigation posture. The tracked data show one case, in which Par is the defendant and never the plaintiff — the profile of an operating generics manufacturer being sued, not an NPE or patent assertor. The sole venue is D.N.J., Par's home district, not a plaintiff-friendly forum such as the Eastern District of Texas. Generic ANDA/Paragraph IV litigation of this kind is routine for Par.

Notable case. Jazz Pharmaceuticals, Inc. v. Par Pharmaceutical, Inc. (D.N.J., filed Dec. 27, 2013) was a Hatch-Waxman suit alleging infringement of 13 Jazz patents (including U.S. Pat. Nos. 6,472,431 and 7,668,730) arising from Par's ANDA for generic Xyrem (sodium oxybate) oral solution; Par counterclaimed for declaratory judgment of noninfringement and invalidity, and the action was consolidated with Jazz's parallel suit against Amneal. Par was later named among generic defendants in follow-on antitrust litigation challenging Xyrem settlement agreements.